Posted: 9 January 2023
Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners
Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced that it is presenting at Biotech Showcase 2023. This year, registered attendees can view Cartherics’ presentation live, and also access a recorded version. With 24×7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.
Dr Ian Nisbet, Chief Operating Officer will be presenting Cartherics’ technology and development program at Biotech Showcase at 2.00pm (PST) on Wednesday 11 January.
Cartherics has established a powerful allogeneic cell therapy platform. Key features include:
- Precisely engineered induced pluripotent stem cells (iPSCs)
- Proprietary CAR constructs and immunosuppressive gene knock-outs
- Proprietary manufacturing process
- Pipeline of immune cell therapies, including CAR-iNK and CAR-iT products
- Focus on solid tumors
- Substantial IP portfolio
Prof Alan Trounson, Cartherics’ CEO, stated, “We are proud to be part of the annual gathering of industry leaders and investors in San Francisco and to have the opportunity to highlight our technology platform and products at Biotech Showcase. We look forward to constructive meetings with potential partners and investors from all over the world.”
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
